WO2012109233A3 - Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein - Google Patents

Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein Download PDF

Info

Publication number
WO2012109233A3
WO2012109233A3 PCT/US2012/024133 US2012024133W WO2012109233A3 WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3 US 2012024133 W US2012024133 W US 2012024133W WO 2012109233 A3 WO2012109233 A3 WO 2012109233A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
recurrence risk
breast cancer
cancer patients
predicting recurrence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/024133
Other languages
English (en)
Other versions
WO2012109233A2 (fr
Inventor
Gordon B. Mills
Zhenlin JU
Kevin Coombes
Bryan HENNESSY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2012109233A2 publication Critical patent/WO2012109233A2/fr
Publication of WO2012109233A3 publication Critical patent/WO2012109233A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des trousses utiles pour la prédiction ou l'estimation du risque de récidive chez un patient atteint d'un cancer du sein auquel on a administré ou que l'on a traité par un médicament anti-œstrogène. L'invention concerne des panels de marqueurs protéiques et des procédés d'utilisation des niveaux d'expression de ces marqueurs protéiques dans le calcul du risque de récidive du cancer et de la probabilité de réponse au traitement.
PCT/US2012/024133 2011-02-07 2012-02-07 Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein Ceased WO2012109233A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161440213P 2011-02-07 2011-02-07
US61/440,213 2011-02-07

Publications (2)

Publication Number Publication Date
WO2012109233A2 WO2012109233A2 (fr) 2012-08-16
WO2012109233A3 true WO2012109233A3 (fr) 2012-10-04

Family

ID=46639155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024133 Ceased WO2012109233A2 (fr) 2011-02-07 2012-02-07 Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein

Country Status (1)

Country Link
WO (1) WO2012109233A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
CA2800557A1 (fr) 2010-04-29 2011-11-03 Medical Prognosis Institute A/S Methodes et dispositifs permettant de predire l'efficacite d'un traitement
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209920A1 (en) * 2002-03-13 2010-08-19 Baker Joffre B Gene Expression Profiling in Biopsied Tumor Tissues
US7569345B2 (en) * 2003-01-15 2009-08-04 Genomic Health, Inc. Gene expression markers for breast cancer prognosis
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMAD ET AL.: "Stromelysin 3: an independent prognostic factor for relapse-free survival in node- positive breast cancer and demonstration of novel breast carcinoma cell expression", AM. J. PATHOL., vol. 152, no. 3, March 1998 (1998-03-01), pages 721 - 728 *
STANWAY ET AL.: "Steroid sulfatase: a new target for the endocrine therapy of breast cancer", ONCOLOGIST, vol. 12, no. 4, April 2007 (2007-04-01), pages 370 - 374 *

Also Published As

Publication number Publication date
WO2012109233A2 (fr) 2012-08-16

Similar Documents

Publication Publication Date Title
EP3208615A3 (fr) Utilisations d'inhibiteurs de hsp90 marqués
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
WO2012006589A3 (fr) Procédés et compositions pour l'identification, l'évaluation et le traitement de cancers associés à des signaux hedgehog
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
WO2012038068A8 (fr) Moyens et procédés pour la prévision de la réponse à un traitement d'un patient cancéreux
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
MY186591A (en) Methods for increasing efficacy of folri cancer therapy
WO2012177595A9 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer
IL225262A0 (en) Methods and compositions for treating lung cancer
PL2535716T3 (pl) Marker nowotworowy i cel terapeutyczny
WO2013083098A3 (fr) Procédé de détermination de la sensibilité médicamenteuse de cellules cancéreuses aux inhibiteurs de l'aurora kinase
SG11202103913WA (en) Method for quantifying molecular activity in cancer cells of a human tumour
WO2012109233A3 (fr) Procédés de prédiction du risque de récidive chez des patients atteints d'un cancer du sein
EP2819575A4 (fr) Structure de cathéter et procédé pour localiser un tissu dans un organe du corps et simultanément, administrer une thérapie et évaluer la thérapie administrée
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2012145535A3 (fr) Modèle animal de cancer humain et procédés pour son utilisation
WO2012170513A3 (fr) Thérapie à base de he4 pour une affection maligne
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
IN2014MN01945A (fr)
WO2013093115A3 (fr) Séquences de marqueurs du cancer du sein et utilisation desdites séquences de marqueurs du cancer du sein
IN2014MN01944A (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12744652

Country of ref document: EP

Kind code of ref document: A2